Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. - Kedar,I.; Mermershtain,W.; Ivgi,H. (Int J Cancer, 2004)